viewBotanix Pharmaceuticals Ltd

Botanix Pharmaceuticals advances eczema study faster than expected

The company is developing BTX 1204, a new treatment for eczema.

scientist in lab
The prescription market generates more than US$8 billion in annual sales globally

Botanix Pharmaceuticals Ltd (ASX:BOT) has completed enrolment of its phase Ib atopic dermatitis patient study for treatment BTX 1204.

Notably, the study enrolment was completed in advance of Botanix management’s initial target, underpinned by significant interest from patients in joining the study.

Botanix is developing BTX 1204, a new treatment for mild to moderate atopic dermatitis, also known as eczema.

The company remains on track to release phase Ib results in June quarter of 2018.

Targeting a market worth US$8 billion in annual sales

Atopic dermatitis is a common chronic inflammatory skin disorder and the prescription market generates more than US$8 billion in annual sales globally.

Patients display achronic rash characterised by inflammation and itching with symptoms lasting 14 days or more.

Before the recent approval of Eucrisa® (crisaborole), there had been no new drugs approved for atopic dermatitis for more than 15 years.

Competing treatment has little to no impact on itch

Based on successful phase III studies, Pfizer Inc (NYSE:PFE) acquired the company that developed Eucrisa®  for US$5.2 billion in May 2016.

Notably, clinical studies showed that Eucrisa® had little to no impact on itch, which remains a key unmet need for atopic dermatitis patients.

Potential to move to phase II this year

Following completion of this study, Botanix plans to file an Investigational New Drug (IND) application with the FDA.

This will allow a multicentre phase II safety and efficacy study for BTX 1204 to potentially commence later in December half of this year.

Quick facts: Botanix Pharmaceuticals Ltd

Price: 0.052 AUD

Market: ASX
Market Cap: $50.58 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Australian Potash CEO says offtake deal with HELM AG is 'defining moment'...

Australian Potash Ltd's (ASX:APC) Matt Shackleton speaks to Proactive's Andrew Scott after signing its fourth binding term sheet for offtake from its Lake Wells Sulphate of Potash (SOP) Project with HELM AG. It's for the supply of 30,000 tonnes per year of K-Brite SOP to the European market. The...

1 hour, 33 minutes ago

2 min read